logo

For the Inventor, By the Inventor

Colfax, WA, United States of America

Mark R Wildung

USPTO Granted Patents = 11

Average Co-Inventor Count = 2.9

ph-index = 5

Forward Citations = 65(Granted Patents)


Company Filing History:

goldMedal11 out of 462 
 
Washington State University
 patents

Years Active: 1999-2006

Loading Chart...
11 patents (USPTO):Explore Patents
1. 7153676 - Transacylases of the paclitaxel biosynthetic pathway (2006-12-26),
2. 6818755 - Nucleic acid molecules encoding 10-deacetylbaccatin III-O-acetyl transferase and related products (2004-11-16),
3. 6610527 - Compositions and methods for Taxol biosynthesis (2003-08-26),
4. 6303330 - Geranyl diphosphate synthase large subunit, and methods of use (2001-10-16),
5. 6287835 - Transacylases of the paclitaxel biosynthetic pathway (2001-09-11),
6. 6258602 - Isolation and bacterial expression of a sesquiterpene synthase cDNA clone from peppermint (mentha x piperita, L.) that produces the aphid alarm pheromone (E)-&bgr;-farnesene (2001-07-10),
7. 6190895 - Nucleic and amino acid sequences relating to a novel transketolase, and methods for the expression thereof (2001-02-20),
8. 6114160 - Compositions and methods for taxol biosynthesis (2000-09-05),
9. 6008043 - Isolation and bacterial expression of a sesquiterpene synthase CDNA (1999-12-28),
10. 5994114 - Compositions and methods for taxol biosynthesis (1999-11-30),
11. 5876964 - Geranyl diphosphate synthase from mint (1999-03-02),

Title: Mark R. Wildung: Innovator in Paclitaxel Biosynthesis

Introduction

Mark R. Wildung, an accomplished inventor based in Colfax, Washington, has made significant contributions in the field of biochemistry, particularly in the biosynthetic pathway of paclitaxel. With a total of 11 patents to his name, his work not only highlights his ingenuity but also emphasizes the potential of enzymes in the production of vital pharmaceuticals.

Latest Patents

Wildung’s latest innovations include groundbreaking patents related to transacylases in the paclitaxel biosynthetic pathway. One of his notable patents discloses transacylase enzymes designed to produce paclitaxel and related taxoids, as well as intermediates in the biosynthetic pathway. Additionally, he has revealed nucleic acid sequences that encode these transacylase enzymes, providing a deeper understanding of their functionality. Another important patent discusses nucleic acid molecules encoding 10-deacetylbaccatin III-O-acetyl transferase and the methods involving these enzymes in producing Taxol™ and intermediates, while further detailing specific enzyme variants like taxadienol 5-O-acetyl transacylase (TAX1) and 10-deacetylbaccatin III-10-O-acetyl transferase (TAX6).

Career Highlights

Mark R. Wildung’s career is anchored at Washington State University, where he works alongside leading researchers and contributors in his field. His consistent dedication to innovation in biochemistry illustrates his important role in enhancing the understanding and application of enzyme-driven processes in pharmaceutical manufacturing.

Collaborations

Throughout his professional journey, Wildung has collaborated with esteemed colleagues, including Rodney Bruce Croteau and Kevin D. Walker. These partnerships have fostered an environment of creativity and scientific exploration, leading to numerous advancements in the biosynthetic pathways of crucial compounds.

Conclusion

In conclusion, Mark R. Wildung stands out as a pioneering inventor in the realm of paclitaxel biosynthesis, holding multiple patents that reflect his expertise and innovative spirit. His ongoing research and collaborations continue to contribute significantly to the field, promising advancements in pharmaceutical production and biosynthetic research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…